908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.…
908 Devices Inc (MASS) (Q3 2026) Earnings Call Highlights: Record $19 Million Revenue, 35% ...
908 Devices (NASDAQ: MASS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 172 employees.
The shares were at 8.670 USD on 20 November 2026, up 11.2% over 52 weeks. Its 52-week range is 5.025 USD to 13.35 USD: the price is 35.0% below the high and 72.5% above the low.
Its market capitalisation is 360.52M USD.
908 Devices reports return on equity of 13.6%, an operating margin of -30.6% and revenue up 35.3% year over year.
It holds more cash than debt, a net cash position of 94.08M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 14.00 USD is 61.5% above the current price. The next earnings report is expected on 2 March 2027.